Johnson & Johnson Dividend & Recent News: Key Updates Before Aug 26, 2025 Ex-Dividend Date

Johnson & Johnson (JNJ) has announced a cash dividend of $1.30 per share, with the ex-dividend date set for Aug 26, 2025. The dividend was officially declared on Jul 16, 2025, and is scheduled to be paid on Sep 9, 2025. This payout is consistent with the company’s most recent dividend on Jun 10, 2025, which was also $1.30 per share. When compared to the average of the last 10 dividend per share amounts—$0.4601279—this latest announcement represents a significant increase. Investors should note that Aug 26, 2025 is the last day to purchase JNJ shares to be eligible for this dividend payment; any purchase after that date will not qualify for the distribution.

Over the past week, JNJ has been in the spotlight due to its significant commitment to expanding its U.S. manufacturing capabilities. The company recently announced a $2 billion investment to enhance its state-of-the-art manufacturing facility in North Carolina, a move expected to create approximately 120 new jobs over the next decade. This investment is part of a broader strategy to strengthen its domestic presence, especially in light of potential pharmaceutical import duties. The facility, located at Fujifilm Biotechnologies’ site in Holly Springs, NC, is dedicated to large-scale biopharmaceutical production and is supported by an existing $3.2 billion investment. JNJ plans to manufacture the majority of its advanced medicines in the U.S., aligning with its long-term vision to lead in healthcare innovation.

Since the last update, the company has emphasized its continued expansion across the U.S. and plans to announce new manufacturing sites in the coming months. This follows a previously announced $55 billion investment boost over four years, which is expected to further support U.S. sales and operational growth. Analysts indicated that the recent One Big Bill Beautiful Act has provided tax incentives and R&D credits, encouraging companies like JNJ to bring more production onshore. Other pharmaceutical firms, including AstraZeneca and Eli Lilly, are also ramping up U.S. operations, reflecting a broader industry trend toward reshoring.

As of late, JNJ’s stock has experienced some volatility, with shares showing mixed reactions to the recent investment announcements. Although the company’s strategic moves aim to bolster long-term growth, the stock's performance has remained cautious due to broader market uncertainties and regulatory pressures. On TipRanks, JNJ maintains a Moderate Buy consensus, with 8 Buy and 10 Hold ratings. The highest price target is currently at $190, though recent market fluctuations suggest investors should remain cautious in the short term.

With the ex-dividend date fast approaching on Aug 26, 2025, investors looking to participate in this dividend should ensure their ownership is reflected by that date. The recent manufacturing investments and ongoing U.S. expansion underscore JNJ’s commitment to long-term stability and growth, offering a compelling backdrop for both dividend and capital appreciation strategies.